文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

婴儿接种13价肺炎球菌结合疫苗的十年公共卫生影响:一项模型分析

Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: A modelling analysis.
PubMed 文献 · Vaccine · 2020-09-08

该模型分析评估了2010至2019年间全球婴儿接种PCV13所避免的肺炎球菌疾病病例和死亡数。

要点

  • 同期估计避免624,904例死亡。
  • 结果支持扩大全球PCV规划覆盖以提升公共卫生影响。

核心结论

  • PCV13婴儿接种在2010至2019年间对全球肺炎球菌疾病和死亡产生了显著的公共卫生影响。

研究设计与样本

  • 模型分析,估计每年接种PCV13的婴儿数及避免的侵袭性肺炎球菌疾病、肺炎球菌肺炎和急性中耳炎病例与死亡数。

主要发现

  • PCV13接种估计在2010至2019年间全球避免了624,904例死亡。

临床怎么用

  • 应重视并扩大全球PCV规划覆盖,以维持和提升PCV13的公共卫生影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pneumococcal disease is a substantial contributor to illness and death in young children globally. The introduction of 7-valent pneumococcal conjugate vaccine (PCV7) in 2000 had a significant impact in preventing pneumococcal disease in both vaccinated children and unvaccinated individuals (through herd effect). A higher valent PCV13 replaced PCV7 in late 2009. This analysis was undertaken to assess how many cases and deaths have been averted over the last decade since PCV13 introduction. A model estimated the number of infants vaccinated annually with PCV13, as well as the number of cases and deaths of invasive pneumococcal disease, pneumococcal pneumonia, and acute otitis media cases averted. PCV13 vaccination was estimated to have prevented 175.2 million cases of all pneumococcal diseases and 624,904 deaths globally between 2010 and 2019. These results demonstrate the substantial public health impact of PCV13 and highlight the importance of increasing the global reach of PCV programs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chapman R, Sutton K, Dillon-Murphy D, et al. Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: A modelling analysis. Vaccine. 2020. PMID: 32912642. doi:10.1016/j.vaccine.2020.08.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。